ArticleAlimentary pharmacology & therapeutics2016
Creation of a model to predict survival in patients with refractory coeliac disease using a multinational registry.
Article in Alimentary pharmacology & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03866538 (Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease-Changing Utility of Serology and Histologic Measures: Expert Review.Gastroenterology · 2019Guideline
- Celiac Disease: A Comprehensive Review of Epidemiology, Pathogenesis, and Therapeutic Strategies.Digestive diseases and sciences · 2026Review
- Nutritional remission without mucosal healing in type II refractory celiac disease: a case report.Frontiers in nutrition · 2026Article
- Malignancies in Celiac Disease-A Hidden Threat with Diagnostic Pitfalls.Biomedicines · 2025Review
- Dietary assessments in individuals living with coeliac disease: key considerations.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2025Review
- Refractory celiac disease and its mimickers: a review on pathogenesis, clinical-pathological features and therapeutic challenges.Frontiers in oncology · 2023Review
- Celiac Disease in the Elderly.Current treatment options in gastroenterology · 2022Article
- The global burden of coeliac disease: opportunities and challenges.Nature reviews. Gastroenterology & hepatology · 2022Review
- Successful novel use of tofacitinib for type II refractory coeliac disease.BMJ case reports · 2022Article
- Refractory Celiac Disease.Current gastroenterology reports · 2020Review
- Diagnosis and Treatment Patterns in Celiac Disease.Digestive diseases and sciences · 2019Review
- Descriptive Study of the Different Tools Used to Evaluate the Adherence to a Gluten-Free Diet in Celiac Disease Patients.Nutrients · 2018Review
- Outcome of Referrals for Non-Responsive Celiac Disease in a Tertiary Center: Low Incidence of Refractory Celiac Disease in the Netherlands.Clinical and translational gastroenterology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundRefractory coeliac disease is a severe complication of coeliac disease with heterogeneous outcome.
aimTo create a prognostic model to estimate survival of patients with refractory coeliac disease.
methodsWe evaluated predictors of 5-year mortality using Cox proportional hazards regression on subjects from a multinational registry. Bootstrap resampling was used to internally validate the individual factors and overall model performance. The mean of the estimated regression coefficients from 400 bootstrap models was used to derive a risk score for 5-year mortality.
resultsThe multinational cohort was composed of 232 patients diagnosed with refractory coeliac disease across seven centres (range of 11-63 cases per centre). The median age was 53 years and 150 (64%) were women. A total of 51 subjects died during a 5-year follow-up (cumulative 5-year all-cause mortality = 30%). From a multiple variable Cox proportional hazards model, the following variables were significantly associated with 5-year mortality: age at refractory coeliac disease diagnosis (per 20 year increase, hazard ratio = 2.21; 95% confidence interval, CI: 1.38-3.55), abnormal intraepithelial lymphocytes (hazard ratio = 2.85; 95% CI: 1.22-6.62), and albumin (per 0.5 unit increase, hazard ratio = 0.72; 95% CI: 0.61-0.85). A simple weighted three-factor risk score was created to estimate 5-year survival.
conclusionsUsing data from a multinational registry and previously reported risk factors, we create a prognostic model to predict 5-year mortality among patients with refractory coeliac disease. This new model may help clinicians to guide treatment and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.